Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Invested Capital (2022 - 2025)

Historic Invested Capital for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $193.7 million.

  • Axsome Therapeutics' Invested Capital fell 2901.12% to $193.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $193.7 million, marking a year-over-year decrease of 2901.12%. This contributed to the annual value of $237.0 million for FY2024, which is 3611.06% down from last year.
  • As of Q3 2025, Axsome Therapeutics' Invested Capital stood at $193.7 million, which was down 2901.12% from $193.1 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Invested Capital ranged from a high of $458.8 million in Q2 2023 and a low of $64.7 million during Q1 2022
  • Over the past 4 years, Axsome Therapeutics' median Invested Capital value was $252.4 million (recorded in 2022), while the average stood at $260.6 million.
  • Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 31633.96% in 2023, then crashed by 3928.96% in 2024.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Invested Capital stood at $204.6 million in 2022, then skyrocketed by 81.36% to $371.0 million in 2023, then crashed by 36.11% to $237.0 million in 2024, then dropped by 18.26% to $193.7 million in 2025.
  • Its Invested Capital was $193.7 million in Q3 2025, compared to $193.1 million in Q2 2025 and $233.2 million in Q1 2025.